Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia

Schizophrenia Research

Volumn 182, Issue , 2017, Pages 90-97

  Dunayevich, Eduardo ^a   Buchanan, Robert W ^b   Chen, Chao Yin ^a   Yang, Jun ^a   Nilsen, Jon ^a   Dietrich, Julie M ^a   Sun, Hong ^a   Marder, Stephen ^c,d  

^a AMGEN INC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Geriatric Research   (United States)

Author keywords

Clinical trial; Glycine; GlyT1; Negative symptoms; Phase 2

Indexed keywords

AMG 747; GLYCINE TRANSPORTER 1; HEMOGLOBIN; NEUROLEPTIC AGENT; PLACEBO; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; (R)-2-(4-(PHENYL(3-(TRIFLUOROMETHYL)PHENYL)METHYL)PIPERAZIN-1-YL)ACETIC ACID; GLYCINE TRANSPORTER; PIPERAZINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; MULTICENTER STUDY; NEGATIVE SYMPTOM ASSESSMENT 16; NEGATIVE SYMPTOM FACTOR SCORE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHEEHAN DISABILITY SCALE; SINGLE BLIND PROCEDURE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85006049219     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.10.027     Document Type: Article

References (33)

1. Alphs, L.D., Summerfelt, A., Lann, H., Muller, R.J., The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol. Bull. 25:2 (1989), 159–163.
2. Axelrod, B.N., Goldman, R.S., Woodard, J.L., Alphs, L.D., Factor structure of the negative symptom assessment. Psychiatry Res. 52:2 (1994), 173–179.
3. Barbui, C., Furukawa, T., Cipriani, A., Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. Can. Med. Assoc. J. 178:3 (2008), 296–305.
4. Bugarski-Kirola, D., Wang, A., Abi-Saab, D., Blattler, T., A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. Eur. Neuropsychopharmacol. 24:7 (2014), 1024–1036.
5. Burns, T., Patrick, D., Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr. Scand. 116:6 (2007), 403–418.
6. Chang, H.J., Lane, H.Y., Tsai, G.E., NMDA pathology and treatment of schizophrenia. Curr. Pharm. Des. 20:32 (2014), 5118–5126.
7. Chen, J., Dias, C., Bragasin, M., Wilson, S., Narayanan, N., Jang, G., Ma, P., Vu, T., Population pharmacokinetic-pharmacodynamic (PKPD) modeling of AMG 747, a glycine transporter type 1 (Glyt1) inhibitor, in healthy subjects. Clin. Pharmacol. Ther., 2015, S79 (WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA).
8. Endicott, J., Nee, J., Harrison, W., Blumenthal, R., Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 29:2 (1993), 321–326.
9. Frohlich, J., Van Horn, J.D., Reviewing the ketamine model for schizophrenia. J. Psychopharmacol. 28:4 (2014), 287–302.
10. Fromer, M., Pocklington, A.J., Kavanagh, D.H., Williams, H.J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D.M., Carrera, N., Humphreys, I., Johnson, J.S., Roussos, P., Barker, D.D., Banks, E., Milanova, V., Grant, S.G., Hannon, E., Rose, S.A., Chambert, K., Mahajan, M., Scolnick, E.M., Moran, J.L., Kirov, G., Palotie, A., McCarroll, S.A., Holmans, P., Sklar, P., Owen, M.J., Purcell, S.M., O'Donovan, M.C., De novo mutations in schizophrenia implicate synaptic networks. Nature 506:7487 (2014), 179–184.
11. Javitt, D.C., Glycine modulators in schizophrenia. Curr. Opin. Investig. Drugs 3:7 (2002), 1067–1072.
12. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:2 (1987), 261–276.
13. Kern, R.S., Nuechterlein, K.H., Green, M.F., Baade, L.E., Fenton, W.S., Gold, J.M., Keefe, R.S., Mesholam-Gately, R., Mintz, J., Seidman, L.J., Stover, E., Marder, S.R., The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am. J. Psychiatry 165:2 (2008), 214–220.
14. Khan, A., Bhat, A., Kolts, R., Thase, M.E., Brown, W., Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?. CNS Neurosci. Ther. 16:4 (2010), 217–226.
15. Kinon, B.J., Gomez, J.C., Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology 66 (2013), 82–86.
16. Krystal, J.H., D'Souza, D.C., Mathalon, D., Perry, E., Belger, A., Hoffman, R., NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl.) 169:3–4 (2003), 215–233.
17. Lahti, A.C., Koffel, B., LaPorte, D., Tamminga, C.A., Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:1 (1995), 9–19.
18. Lane, H.Y., Chang, Y.C., Liu, Y.C., Chiu, C.C., Tsai, G.E., Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62:11 (2005), 1196–1204.
19. Lechner, S.M., Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr. Opin. Pharmacol. 6:1 (2006), 75–81.
20. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, I., Clifton, A., Pickar, D., Breier, A., Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:3 (1997), 141–150.
21. Marder, S.R., Davis, J.M., Chouinard, G., The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychol. 58:12 (1997), 538–546.
22. Maruff, P., Thomas, E., Cysique, L., Brew, B., Collie, A., Snyder, P., Pietrzak, R.H., Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch. Clin. Neuropsychol. 24:2 (2009), 165–178.
23. Moller, H.J., Demyttenaere, K., Olausson, B., Szamosi, J., Wilson, E., Hosford, D., Dunbar, G., Tummala, R., Eriksson, H., Two phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. World J. Biol. Psychiatry 16:7 (2015), 483–501.
24. Nuechterlein, K.H., Green, M.F., Kern, R.S., Baade, L.E., Barch, D.M., Cohen, J.D., Essock, S., Fenton, W.S., Frese, F.J. III, Gold, J.M., Goldberg, T., Heaton, R.K., Keefe, R.S., Kraemer, H., Mesholam-Gately, R., Seidman, L.J., Stover, E., Weinberger, D.R., Young, A.S., Zalcman, S., Marder, S.R., The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165:2 (2008), 203–213.
25. Pietrzak, R.H., Olver, J., Norman, T., Piskulic, D., Maruff, P., Snyder, P.J., A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J. Clin. Exp. Neuropsychol. 31:7 (2009), 848–859.
26. Ritsner, M., Kurs, R., Gibel, A., Ratner, Y., Endicott, J., Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual. Life Res. 14:7 (2005), 1693–1703.
27. Rutherford, B.R., Pott, E., Tandler, J.M., Wall, M.M., Roose, S.P., Lieberman, J.A., Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiat. 71:12 (2014), 1409–1421.
28. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:7510 (2014), 421–427.
29. Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A., The measurement of disability. Int. Clin. Psychopharmacol. 11:Suppl. 3 (1996), 89–95.
30. Tsai, G.E., Lin, P.Y., Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 16:5 (2010), 522–537.
31. Tsai, G., Lane, H.Y., Yang, P., Chong, M.Y., Lange, N., Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55:5 (2004), 452–456.
32. Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E.A., Ostland, M., Wallace, T.L., Knoflach, F., Dorflinger, E., Wettstein, J.G., Bausch, A., Garibaldi, G., Santarelli, L., Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiat. 71:6 (2014), 637–646.
33. Vandenberg, R.J., Aubrey, K.R., Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin. Ther. Targets 5:4 (2001), 507–518.